{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T23:13:19Z","timestamp":1761520399419,"version":"build-2065373602"},"reference-count":13,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinical-colorectal-cancer.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Colorectal Cancer"],"published-print":{"date-parts":[[2021,12]]},"DOI":"10.1016\/j.clcc.2021.09.004","type":"journal-article","created":{"date-parts":[[2021,9,14]],"date-time":"2021-09-14T22:35:45Z","timestamp":1631658945000},"page":"359-363","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Standard-Dose Trifluridine\/Tipiracil as Safe Treatment Alternative in Metastatic Colorectal Cancer Patients With DPD Deficiency"],"prefix":"10.1016","volume":"20","author":[{"given":"Jeroen F.","family":"Schouten","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeroen","family":"Willems","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefan J.W.J.","family":"Sanders","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Geert-Jan","family":"Creemers","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4389-6420","authenticated-orcid":false,"given":"Maarten J.","family":"Deenen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clcc.2021.09.004_bib0001","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.ctrv.2016.08.002","article-title":"Improving safety of fluoropyrimidine chemotherapy by individualizing treatment based on dihydropyrimidine dehydrogenase activity - Ready for clinical practice?","volume":"50","author":"Meulendijks","year":"2016","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.clcc.2021.09.004_bib0002","unstructured":"EMA. EMA recommendations on DPD testing prior to treatment with fluorouracil, capecitabine, tegafur and flucytosine. https:\/\/www.ema.europa.eu\/en\/news\/ema-recommendations-dpd-testing-prior-treatment-fluorouracil-capecitabine-tegafur-flucytosine. Published 2020. Accessed June 17, 2020."},{"key":"10.1016\/j.clcc.2021.09.004_bib0003","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1002\/cpt.911","article-title":"Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for dihydropyrimidine dehydrogenase genotype and fluoropyrimidine dosing: 2017 Update","volume":"103","author":"Amstutz","year":"2018","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.clcc.2021.09.004_bib0004","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.1016\/S1470-2045(15)00286-7","article-title":"Clinical relevance of DPYD variants c.1679T>G, c.1236G>A\/HapB3, and c.1601G>A as predictors of severe fluoropyrimidine-associated toxicity: a systematic review and meta-analysis of individual patient data","volume":"16","author":"Meulendijks","year":"2015","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clcc.2021.09.004_bib0005","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1056\/NEJMoa1414325","article-title":"Randomized trial of TAS-102 for refractory metastatic colorectal cancer","volume":"372","author":"Mayer","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clcc.2021.09.004_bib0006","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1007\/s40265-016-0633-9","article-title":"Trifluridine\/tipiracil: a review in metastatic colorectal cancer","volume":"76","author":"Burness","year":"2016","journal-title":"Drugs"},{"key":"10.1016\/j.clcc.2021.09.004_bib0007","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.ejca.2019.03.013","article-title":"Fluoropyrimidines and DPD testing: is there truly an inexorable link?","volume":"113","author":"Milano","year":"2019","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.clcc.2021.09.004_bib0008","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1016\/j.ctrv.2015.06.001","article-title":"TAS-102, a novel antitumor agent: a review of the mechanism of action","volume":"41","author":"Lenz","year":"2015","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.clcc.2021.09.004_bib0009","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.2217\/pgs.15.70","article-title":"Translating DPYD genotype into DPD phenotype: using the DPYD gene activity score","volume":"16","author":"Henricks","year":"2015","journal-title":"Pharmacogenomics"},{"key":"10.1016\/j.clcc.2021.09.004_bib0010","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1200\/JCO.2015.63.1325","article-title":"Upfront genotyping of DPYD*2A to individualize fluoropyrimidine therapy: a safety and cost analysis","volume":"34","author":"Deenen","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clcc.2021.09.004_bib0011","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1016\/S1470-2045(18)30686-7","article-title":"DPYD genotype-guided dose individualisation of fluoropyrimidine therapy in patients with cancer: a prospective safety analysis","volume":"19","author":"Henricks","year":"2018","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clcc.2021.09.004_bib0012","first-page":"310","article-title":"Safety report of TAS-102 in a patient with reduced DPD activity","volume":"18","author":"Bolzacchini","year":"2019","journal-title":"Clin Colorectal Cancer"},{"issue":"Md","key":"10.1016\/j.clcc.2021.09.004_bib0013","first-page":"1","article-title":"Capecitabine therapy and DPYD genotype","author":"Dean","year":"2012","journal-title":"Med Genet Summ"}],"container-title":["Clinical Colorectal Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1533002821000906?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1533002821000906?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T23:07:22Z","timestamp":1761520042000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1533002821000906"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12]]},"references-count":13,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["S1533002821000906"],"URL":"https:\/\/doi.org\/10.1016\/j.clcc.2021.09.004","relation":{},"ISSN":["1533-0028"],"issn-type":[{"type":"print","value":"1533-0028"}],"subject":[],"published":{"date-parts":[[2021,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Standard-Dose Trifluridine\/Tipiracil as Safe Treatment Alternative in Metastatic Colorectal Cancer Patients With DPD Deficiency","name":"articletitle","label":"Article Title"},{"value":"Clinical Colorectal Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clcc.2021.09.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}